Salud financiera de hoja de balance de Travere Therapeutics
Salud financiera controles de criterios 4/6
Travere Therapeutics tiene un patrimonio de los accionistas total de $200.8M y una deuda total de $377.3M, lo que sitúa su ratio deuda-patrimonio en 187.9%. Sus activos y pasivos totales son $788.9M y $588.1M respectivamente.
Información clave
509.9%
Ratio deuda-patrimonio
US$377.69m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$441.04m |
| Patrimonio | US$74.07m |
| Total pasivo | US$589.48m |
| Activos totales | US$663.55m |
Actualizaciones recientes sobre salud financiera
Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 22
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Jun 09Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 16Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Oct 06Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Jun 19Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 07Recent updates
Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now
May 02Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop
Apr 20Travere Therapeutics: Restructuring Away From Disaster
Jan 30Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 22Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)
Aug 08Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Jun 09It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks
May 05Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 16Travere Therapeutics' FDA target action date for nephropathy treatment extended
Oct 13Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Oct 06Travere Therapeutics: Changes In The Risk-Reward Assessment
Sep 29Travere, CSL kidney disease drug sparsentan gets review in EU
Aug 22Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M
Aug 04Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'
Jul 14Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Jun 19Travere Therapeutics: Strong Sell, Ticking Time Bomb, We Are Passing
Apr 11Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 07Travere Therapeutics: Tarpeyo's Approval Is Good News
Jan 31Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?
Oct 07Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success
Aug 30Travere: Setback Presents Cautious Opportunity
Jul 18Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?
Jul 09Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($616.8M) de TVTX superan a sus pasivos a corto plazo ($177.9M).
Pasivo a largo plazo: Los activos a corto plazo de TVTX ($616.8M) superan a sus pasivos a largo plazo ($410.2M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: TVTX tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de TVTX ha crecido de 68.4% a 187.9% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: TVTX tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si TVTX tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.